1228694-82-3

Upstream product

• 331-39-5 caffeic acid 
• 100-01-6 4-nitro-aniline 
• 331-39-5 caffeic acid 
• 77201-71-9 (E)-3-(3,4-dihydroxyphenyl)acryloyl chloride 

Relevant academic research and scientific papers

Novel Chlorogenic Acid Derivatives and Composition for Treating Inflammatory Disease Comprising the Same

The present invention relates to a novel chlorogenic acid derivative compound having anti-inflammatory activities and an anti-inflammatory composition comprising the same as an active ingredient. The chlorogenic acid derivative compound of the present invention inhibits overproduction of nitrogen oxide (NO) induced by treating LPS in macrophage. The chlorogenic acid derivative compound of the present invention suppresses activation of NF-κB which is a signal transmission-mediated transcription factor significant in an oxidative stress and inflammation-promoting path. The chlorogenic acid derivative compound of the present invention can be developed as medicine for various inflammatory diseases by inhibiting overproduction of nitrogen oxide and activation of NF-κB.

Skin Whitening Composition Comprising Caffeic Acid Derivatives as the Active Ingredients

The present invention relates to a skin whitening composition containing a new caffeic acid derivative compound as an active ingredient. According to the present invention, the caffeic acid derivative compound can be developed for a skin whitening cosmetic product or for a medicine for the hyperpigmentation of melanin because having skin whitening activity by inhibiting the biosynthesis of melanin in melanocytes.

Synthesis and biological evaluation of caffeic acid derivatives as potent inhibitors of α-MSH-stimulated melanogenesis

We have disclosed our effort to develop caffeic acid derivatives as potent and non-toxic inhibitors of α-MSH-stimulated melanogenesis to treat pigmentation disorders and skin medication including a cosmetic skin-whitening agent. The SAR studies revealed t

Novel Chlorogenic Acid Derivatives and Composition for Treating Inflammatory Disease Comprising the Same

The present invention relates to a novel chlorogenic acid derivative compound having anti-inflammatory activities and to an anti-inflammatory composition including the same as an active ingredient. The chlorogenic acid derivative compound of the present invention controls the overproduction of nitrogen oxide (NO) derived by the treatment of LPS in histiocytes. The chlorogenic acid derivative compound of the present invention inhibits the activation of NF-κB which is an important signal transmittal intermediated transcription factor in oxidant stress and inflammation promoting routes. The chlorogenic acid derivative compound of the present invention has a high possibility of being developed into an agent for treating various inflammatory diseases by inhibiting the overproduction of NO and the activation of NF-κB.

Synthesis, structure and structure-activity relationship analysis of caffeic acid amides as potential antimicrobials

A series of caffeic acid amides 1-23 were synthesized and nine of which (13-17, 19-21 and 23) were reported for the first time. The chemical structures of these compounds were confirmed by means of 1H NMR, ESI MS and elemental analyses. Compound 15 was determined by single-crystal X-ray diffraction analysis. All of the compounds were assayed for antibacterial (Bacillus subtilis, Escherichia coli, Pseudomonas fluorescens and Staphylococcus aureus) and antifungal (Aspergillus niger, Candida albicans and Trichophyton rubrum) activities by MTT method. Compounds 10-12, 15, 18 and 21 showed considerable antibacterial activities against B. subtilis with MICs of 7.95, 6.25, 3.89, 1.18, 3.12 and 15.5?μg/mL, respectively. Structure-activity relationship analysis disclosed that caffeic acid anilides with electron-donating groups at p-position of benzene ring have better inhibitory activities.